<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161554">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02051595</url>
  </required_header>
  <id_info>
    <org_study_id>201300857</org_study_id>
    <nct_id>NCT02051595</nct_id>
  </id_info>
  <brief_title>The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery</brief_title>
  <official_title>The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotics are routinely used to prevent surgical wound infection. Vancomycin is a widely
      used antibiotic for surgery in patients with an allergy to penicillin. During cardiac
      surgery, cardiopulmonary bypass (CPB) and modified ultrafiltration (MUF) are routinely used
      and can lower the level of the antibiotic. The purpose of this study is to quantify the
      change in  plasma  vancomycin concentration associated with cardiopulmonary bypass and
      modified ultrafiltration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects having cardiac surgery in which they will be on a heart-lung machine and will
      receive the antibiotic vancomycin, will be able to participate.

      During the surgery once receiving vancomycin, several samples of blood will be collected to
      test the vancomycin levels.  Participation will be complete once the cardiac surgery has
      been finished.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Circulating vancomycin concentration</measure>
    <time_frame>Study participants will be in this study until the end of their surgery.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples to monitor the vancomycin concentration will be collected at several time points during surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Vancomycin Concentration</condition>
  <arm_group>
    <arm_group_label>Vancomycin concentrations</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vancomycin concentrations will be collected in subjects who are to undergo cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vancomycin concentrations</intervention_name>
    <description>Vancomycin concentrations will be collected in subjects who are to undergo cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.</description>
    <arm_group_label>Vancomycin concentrations</arm_group_label>
    <other_name>pharmacodynamics</other_name>
    <other_name>vancomycin monitoring</other_name>
    <other_name>serum concentrations of vancomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo cardiac surgery with cardiopulmonary bypass and    modified
             ultrafiltration

          -  age greater than 18 years old

          -  penicillin allergy or in-hospital stay greater than 24 hours

          -  normal renal function

          -  normal liver function

          -  absence of clinical and laboratory signs of infection

        Exclusion Criteria:

          -  vancomycin allergy

          -  pregnancy

          -  impaired renal function

          -  impaired liver function

          -  morbid obesity

          -  active infections

          -  Jehovah's Witness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ettore Crimi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith M. Wishin, BSN</last_name>
    <phone>352-494-3165</phone>
    <email>jwishin@anest.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ettore Crimi, MD</last_name>
    <phone>617-697-2861</phone>
    <email>ecrimi@anest.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UF Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Wishin</last_name>
      <phone>352-494-3165</phone>
      <email>jwishin@anest.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Ettore Crimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart lung machine</keyword>
  <keyword>blood pump</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>circulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
